Vancomycin Therapy for Neonatal Sepsis

Rationale for Vancomycin Use

Thrombocytopenia is a recognized clinical sign of neonatal sepsis, particularly late-onset sepsis caused by gram-positive organisms, according to the American Academy of Pediatrics 1
Vancomycin is the primary treatment for serious MRSA infections in the neonatal period and is considered first-line therapy for suspected or confirmed gram-positive infections in neonates, as recommended by the Infectious Diseases Society of America 1, 2

For neonatal sepsis, especially late-onset sepsis, vancomycin is recommended as empiric therapy when MRSA or coagulase-negative staphylococci are suspected, as per the Centers for Disease Control and Prevention guidelines 1
In neonates with necrotizing enterocolitis, Candida is not uncommon and more likely to represent a true pathogen, requiring appropriate antimicrobial coverage including vancomycin, according to the American Academy of Pediatrics 3

Vancomycin dosing in neonates should follow established guidelines as outlined in reference sources, with careful attention to gestational age, postnatal age, and renal function, as recommended by the American Academy of Pediatrics 1

For localized infections in full-term neonates, topical mupirocin may be adequate for mild cases, as suggested by the Infectious Diseases Society of America 1
Clindamycin and linezolid are alternatives for non-endovascular infections in neonates with susceptible isolates, according to the Centers for Disease Control and Prevention 1, 2

Blood cultures should be obtained before starting antibiotics whenever possible, but treatment should not be delayed if sepsis is suspected, as recommended by the American College of Physicians 4
Vancomycin should be discontinued if cultures remain negative after 48-72 hours and there is no clinical evidence of infection, according to the Infectious Diseases Society of America 4